Skip to main content

Latest News

Accutar Biotech’s side chain flexible docking platform assists the discovery of bisubstrate inhibitors of nicotinamide N -methyltransferase (NNMT)

Jan 10,  2018
Figure: Side chain flexible docking model (in green) enables the chimera design of two ligand fragments (in yellow and pink). A bisubstrate nicotinamide N-methyltransferase (NNMT) inhibitor was developed with the aid of Accutar Biotech’s platform recently. The binding pose of the designed inhibitor with human recombinant NNMT was predicted by Accutar Biotech’s side chain flexible docking method. The docking result was further validated...
Read More

Dr. Jie Fan presents Accutar Biotech’s proprietary deep neural network framework at the Artificial Intelligence in Drug Discovery Congress in London

Sep 27,  2017
Read More

Publication of drug binding pocket side chain prediction by deep neural network

Jul 16,  2017
Using a deep neural network architecture without physics-based assumptions, Accutar Biotech has demonstrated that side chain conformation prediction accuracy can be improved by more than 25%, especially for aromatic residues compared with current standard methods. Read more
Read More